Celator Pharmaceuticals Inc (CPXX) was Downgraded by Stifel to ” Hold”. Earlier the firm had a rating of “Buy ” on the company shares. Stifel advised their investors in a research report released on Jun 1, 2016.
Many Wall Street Analysts have commented on Celator Pharmaceuticals Inc. Shares were Downgraded by ROTH Capital on May 31, 2016 to ” Neutral” and Lowered the Price Target to $ 26 from a previous price target of $30.25 .Stifel Initiated Celator Pharmaceuticals Inc on Apr 22, 2016 to “Buy”, Price Target of the shares are set at $23.Needham Initiated Celator Pharmaceuticals Inc on Apr 12, 2016 to “Buy”, Price Target of the shares are set at $24.
On the company’s financial health, Celator Pharmaceuticals Inc reported $-0.16 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on May 10, 2016. Analyst had a consensus of $-0.14.
Celator Pharmaceuticals Inc opened for trading at $17.69 and hit $17.69 on the upside on Friday, eventually ending the session at $17.53, with a gain of 0.17% or 0.03 points. The heightened volatility saw the trading volume jump to 11,46,966 shares. Company has a market cap of $745 M.
In a different news, on Dec 7, 2015, Scott D Morenstein (director) purchased 5,000 shares at $1.87 per share price. According to the SEC, on Oct 7, 2015, Scott Thomas Jackson (CEO) purchased 14,450 shares at $1.74 per share price. On Oct 5, 2015, Fred M Powell (CFO) purchased 13,700 shares at $1.78 per share price, according to the Form-4 filing with the securities and exchange commission.
Celator Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing products to cure cancer. Celator’s technology platform CombiPlex offers the rational design and rapid evaluation of combinations incorporating traditional chemotherapies as well as molecularly targeted agents to deliver anti-cancer activity. The Company’s products are in research and development phases. Celator’s lead product is CPX-351 a liposomal formulation of cytarabine:daunorubicin for the treatment of acute myeloid leukemia. The Company owns worldwide development and commercialization rights to CPX-351. The Company’s other pipeline products includes CPX-1 a liposomal formulation of irinotecan:floxuridine for the treatment of colorectal cancer and a preclinical stage product candidate CPX-8 a hydrophobic docetaxel prodrug nanoparticle formulation.